



**THE CONNECTICUT SINO-AMERICAN PHARMACEUTICAL PROFESSIONALS  
ASSOCIATION (SAPA-CT) 2<sup>ND</sup> ANNUAL CONFERENCE**

**COOPERATION BETWEEN US AND CHINA IN TODAY'S  
PHARMACEUTICAL WORLD  
– CHALLENGES AND OPPORTUNITIES**

**March 22, 2015**

**Davies Auditorium, Yale University  
(10 Hillhouse Ave., New Haven, Connecticut)**

**Hosted by Association of Chinese Students and Scholars at Yale**



**耶魯大學中國學生學者聯合會**  
Association of Chinese Students and Scholars at Yale

## 8:15 – 9:00 am Registration

---

### Introduction

*Session Chairs: Yongmei Li, Ph.D.; Xiaohui Mei, Ph.D.*

*(9:00 – 9:40 am)*

9:00 – 9:05 am

Charles Xie, M.D., Ph.D., President, SAPA-CT (2014-2015): Congratulations

9:05 – 9:10 am

Xiaohui Mei, Ph.D., General Secretary: Announcement of SAPA-CT Election Results

Yongmei Li, Ph.D., President SAPA-CT (2015-2016)

9:10 – 9:15 am

Dongbai Ye, M.S., Counselor for Science & Technology in the Consulate General of the P. R. China in New York

9:15 – 9:30 am

Ning Yan, Ph.D., President, SAPA-HQ

Weiguo Dai, Ph.D., President-elected, SAPA-HQ

Qiao Lu, Ph.D. Candidate, President, Chinese Students & Scholars at Yale

9:30 – 9:40 am

John Schuyler, Chairman, Connecticut District Export Council

**NOTES ON 30 YEARS OF THE CONNECTICUT-SHANDONG RELATIONSHIP AND IMPLICATIONS FOR CONNECTING TECHNOLOGY AND ENTREPRENEURS TODAY**

---

## Global Development of Pharmaceutical and Biotechnology Industry

*Session Chairs: Zhongyu Wang, M.S.; Yingkai Wang, Ph.D.*

*(9:40 – 11:25 am)*

9:40 – 10:05 am

John Houston, Ph.D., Senior Vice President, Disease Sciences & Biologics, Bristol-Myers Squibb Company

### **DRUG DISCOVERY AT BRISTOL-MYERS SQUIBB**

*At Bristol-Myers Squibb our mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. This talk outlines how we approach this mission.*

10:05 – 10:30 am

Milind Deshpande, Ph.D., President and CEO, Achillion

**ACHILLION PHARMACEUTICALS & EXTERNAL PARTNERSHIPS: SYNERGIES IN GLOBAL PHARMACEUTICAL RESEARCH AND DEVELOPMENT**

*Achillion Pharmaceuticals is at the forefront of transforming innovation into novel therapies to address patient needs. We are focused on developing small molecule therapies for Hepatitis C and Complement-related immune disorders. Using integrated capabilities, we have successfully advanced therapies from the bench to the patient. An overview of Achillion Pharmaceuticals including the Scientific and Business vision for building global cooperative R&D will be presented.*

10:30 – 11:00 am

Break

11:00 – 11:25 am

Susan Froshauer, Ph.D., President and CEO, Connecticut United for Research Excellence (CURE)

**GROWTH OF CT BIOSCIENCE: CONNECTING TECHNOLOGY, ENTREPRENEURS, EXPERTS AND COMPANIES**

*CURE ([www.cureconnect.org](http://www.cureconnect.org)) is a 20 year old CT not-for-profit focused on promoting and connecting the CT bioscience community and its stakeholders. We use educational events and one on one mentoring and traditional business development formats to foster knowledge exchange, technology development and job creation. With the CURE Board at its core, and the wide- and diverse membership as its framework the CURE strives to help its community by offering access to the best expertise, investors and technology network possible to support and grow companies, identify, recruit and cultivate talent. We also maintain a watching brief on Federal and State legislative matters, including IP, regulatory, government grants and tax benefits supportive of the biopharmaceutical community. Finally, at the CURE Innovation Commons, we are building a mentoring and resource incubator with offices, co-working, co-laboratory and teaching lab spaces suitable to house and support mentors, service providers, start-ups and growing companies alike. An overview of CURE will be presented.*

---

**Panel Discussion**

Session Chairs: Mingqing Cai, Ph.D.; Qiang Zhang, Ph.D.

(11:25 – 12:00 pm)

---

**Complementary Lunch**

(12:00 – 1:00 pm)

---

## Growth in Pharmaceutical and Biotechnology Industry: Challenges and Opportunities

Session Chairs: Jin Zhou, Ph.D.; Qiao Lu, Ph.D. Candidate

(1:00 - 2:15 pm)

1:00 – 1:25 pm

Everett Hoekstra, Senior Vice President, Finance, Boehringer Ingelheim Pharma. Inc.

### **PHARMACEUTICAL INNOVATION AND VALUE BASED HEALTHCARE ... FRIENDS OR FOES?**

*The increasing cost and complexity of pharmaceutical innovation seems to be on a collision course with society's ability to afford (and/or its willingness to pay for) the growing cost of healthcare. Can healthcare innovation and value-based healthcare thrive together, or are they mutually exclusive? The answers to this compelling question are, and will be, indeed difficult, but perhaps a common starting point might be the key.*

1:25 – 1:50 pm

Shoufeng Li, Ph.D., CEO, Aucta Pharmaceuticals, LLC

### **STARTUP PRODUCT DEVELOPMENT COMPANY IN U.S. AND CHINA: A PERSONAL EXPERIENCE**

*The pharma industry is undergoing significant changes both structurally and in its business focus, evidenced by all pharmaceutical professionals. While the changes can be painful and unsettling at times, it is likely the necessary steps needed in order to maintain pharma companies' long term growth and return on investment. In the same time, China is undergoing unprecedented changes, driven by its population growth, healthcare reform and overall healthcare system upgrade. We believe both changes create many opportunities for pharmaceutical entrepreneurs with the right expertise. The next 5-10 years will witness one of the few remaining fundamental changes in China's healthcare and pharmaceutical arena, creating institutions capable to compete on the global stage, whereas the changes in the U.S. also likely to benefit those with the right skill set and proper business focus. In this presentation, the presenter will share some of his own personal experience in the past few years, setting up a drug development R&D organization, working with partners in both U.S. and China and put together a supporting system that is necessary for the company to operate and compete. The presenter will also share the intangible elements that are important for a transition from a R&D scientist to an operation manager and entrepreneur.*

1:50 – 2:15 pm

John P. Jasper, Ph.D., CSO, Nature's Fingerprint

### **BIO/PHARMACEUTICAL PROCESS PATENT PROTECTION: PROTECTING INTELLECTUAL PROPERTY VIA AMBIENT STABLE ISOTOPES**

*The ambient distribution of light stable isotopes in biopharmaceutical synthetic pathways permits the identification and differentiation of potentially-infringing pathways. After reviewing three cases of product identification, we examine three cases of process authentication, protecting \$1.5 billion in biopharmaceutical products: one of false advertising and two of process patent infringement. The three cases of product authentication demonstrate the dynamic range of the light stable isotopes in differentiating sources of pharmaceutical materials.*

---

## Panel Discussion

Session Chairs: Alan Lin, MBA and Xin Guo, Ph.D.

(2:15 – 2:40 pm)

---

2:40 – 3:00 pm Break

---

## Focus on Success: Achieving Personal and Business Goals

Session Chairs: Ruobing Xia, MBA, John Shen, Ph.D. and Linshu Li, Ph.D. Candidate

(3:00 - 5:00 pm)

- Corporate Career, To Learn from Peers on Their Successful Stories;
- Entrepreneurship, To Grasp Opportunities and Turn Challenges into Success

Philip Zhang, Ph.D., J.D., Chairman & Co-Managing Principal, Milstein Zhang&Wu LLC

### **PASSION AND COMMITMENT: DRIVERS FOR ENTREPRENEURSHIP SUCCESS**

*Entrepreneurship spirit is found in many of us. Some of us take the leap and embark on that endeavor. A few people succeed but many don't. Some embrace entrepreneurship with an idealistic ideal only to find the reality to be something very different: financial hardship, stress, loneliness and insurmountable obstacles. Others persevere through a lengthy, physically demanding and mentally challenging process, eventually achieving what they never would have thought they could. The talk will explore the many aspects of entrepreneurship and attempt to understand what it takes to overcome adversity and become successful.*

James Jin, Ph.D., Vice President, Biocytogen LLC.

### **GENE TARGETING SERVICES AND ENTREPRENEURIAL OPPORTUNITY**

*James's talk will focus on the development and application of gene targeting technology. He will also share his own insight and experiences on Entrepreneurship.*

### **Panelists:**

Peter Farina, Ph.D., Executive in Residence, Canaan Partners

Yu Cheng, Ph.D., Executive Director, Commercial Strategy and Operations, Boehringer Ingelheim Pharma. Inc.

Yugang Rong, Vice President, Sichuan Kelun Pharmaceutical Research Institute

Yirong Wang, M.Sc., Associate Director, Icahn School of Medicine @Mount Sinai

---

**Dinner Banquet**  
**(The Q Clubhouse, 221 Church Street, New Haven, CT)**

(5:00 - 8:00 pm)

5:30 – 5:45 pm

Service Award Ceremony

5:45 – 6:05 pm

Susie Cheng, Ph.D., J.D., Partner, Leason Ellis LLP

**HOW TO OBTAIN A U.S. PATENT-A CASE STUDY**

*Scientists and entrepreneurs recognize the importance of patents from the perspective of technological innovation as well as asset valuation. However, most find it difficult to navigate the legal aspects of the patent process. Using a concrete Example, this presentation describes the patent application process, from the drafting of a patent application to the grant of a patent. The presentation identifies potential obstacles and practical suggestions for overcoming the obstacles, helping scientists and entrepreneurs in the biomedical/pharmaceutical field who wish to expand the scope of their research and grow their business. In order to obtain patent rights in an invention, the applicant must file a patent application with the United States Patent and Trademark Office (“USPTO”). Generally, the first disclosure of an invention in the biomedical field is in the form of a manuscript. A patent application differs from a manuscript but can be developed from a manuscript. A patent application has a specification which is a detailed description of the invention and how it works. It includes various embodiments which are variations and alternatives to the invention and includes examples. It also contains data and figures that help to illustrate the detailed description. The most important part of a patent application is the claim section. It characterizes and defines the protected invention with exactitude. The claims are examined by the Examiner for which granting of the patent are based. Each claim contains the elements that are present in the invention and dictates the extent of what is being protected. Patent Examiners who are trained in specific scientific or engineering disciplines in the USPTO will examine the application. The Examiner performs a series of searches to identify “prior art” in the field related to the invention. Based on the search results and the subject matter of the claimed invention, the Examiner determines whether the application satisfies all the criteria for patentability. After one or more rounds of communications with the Examiner, there are three possible outcomes. The patent application may be allowed and a patent is granted by the USPTO; the Examiner rejects the application and the applicant appeals the decision of the Examiner; or the Examiner rejects the application and the applicant abandons the application.*

---

## Sponsors



---

## Auditorium & Parking Directions



**Davies Auditorium**  
(10 Hillhouse Ave., New Haven)

**The Q Clubhouse**  
(221 Church Street, New Haven)

**\*Free street parking**

---

Website: <http://www.sapa-ct.org>

: Friends and Members of SAPA-Connecticut

: [SAPAConn@yahoo.com](mailto:SAPAConn@yahoo.com)

